Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics

Ikuo Kobayashi, Kazuro Ikawa, Kogenta Nakamura, Genya Nishikawa, Keishi Kajikawa, Takahiko Yoshizawa, Masahito Watanabe, Yoshiharu Kato, Kenji Zennami, Kent Kanao, Motoi Tobiume, Yoshiaki Yamada, Kenji Mitsui, Masahiro Narushima, Norifumi Morikawa, Makoto Sumitomo

研究成果: Article査読

11 被引用数 (Scopus)

抄録

This study aimed to investigate the penetration of PIPC-TAZ into human prostate, and to assess effectiveness of PIPC-TAZ against prostatitis by evaluating site-specific PK-PD. Patients with prostatic hypertrophy (n=47) prophylactically received a 0.5h infusion of PIPC-TAZ (8:1.2-0.25g or 4-0.5g) before transurethral resection of the prostate. PIPC-TAZ concentrations in plasma (0.5-5h) and prostate tissue (0.5-1.5h) were analyzed with a three-compartment PK model. The estimated model parameters were, then used to estimate the drug exposure time above the minimum inhibitory concentration for bacteria (T>MIC, the PD indicator for antibacterial effects) in prostate tissue for six PIPC-TAZ regimens (2.25 or 4.5g; once, twice, three times or four times daily; 0.5h infusions). Prostate tissue/plasma ratio of PIPC was about 36% both for the maximum drug concentration (Cmax) and the area under the drug concentration-time curve (AUC). Against MIC distributions for isolates of Escherichia coli, Klebsiella species and Proteus species, regimens of 4.5g twice daily and 2.25g three times daily achieved a >90% probability of attaining the bacteriostatic target for PIPC (30% T>MIC) in prostate tissue; regimens of 4.5g three times daily and 2.25g four times daily achieved a >90% probability of attaining the bactericidal target for PIPC (50% T>MIC) in prostate tissue. However, against Pseudomonas aeruginosa isolates, none of the tested regimens achieved a >90% probability. PIPC-TAZ is appropriate for the treatment of prostatitis from the site-specific PK-PD perspective.

本文言語English
ページ(範囲)575-580
ページ数6
ジャーナルJournal of Infection and Chemotherapy
21
8
DOI
出版ステータスPublished - 01-08-2015
外部発表はい

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

フィンガープリント 「Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル